Genovis Stock

Genovis EBIT Margin

The EBIT Margin (Operating Margin) of Genovis (GENO.ST) as of Aug 9, 2026 is 21.32 %. In the previous year, EBIT Margin (Operating Margin) was 35.08 % — a change of -39.23% (lower).

EBIT Margin

21.32 %

YoY

-39.23%

Last updated:

EBIT Margin (Operating Margin) of Genovis is 2026 21.32 % . EBIT Margin (Operating Margin) of Genovis was 2025 35.08 % . It decreases by -39.23% lower compared to the previous year.

Genovis's operating (EBIT) margin stands at 21.3%, down from 26.4% several years earlier.

Access this data via the Eulerpool API

Genovis Stock analysis

What does Genovis do? Genovis AB is a Swedish company that offers biotechnology solutions for drug research and diagnostic industries. The company was founded in Lund, Sweden in 1999 and currently employs over 30 employees. Genovis began with the development of enzymes for protein-based therapeutics, but over time expanded its business to include enzymes for improved analysis methods in mass spectrometry. Genovis has become a leading provider of innovative enzyme solutions and proteomics tools for biomedical research. The company's business model is based on providing specially developed enzymes and proteomics tools to companies in drug research and diagnostic industries. Genovis has two main business areas: marketing enzymes and providing peptide synthesis services. The first business area is the marketing of enzymes for the separation of glycosylated proteins in mass spectrometry. The company develops and produces these enzymes for various applications such as Alzheimer's research, cancer research, and infectious diseases. Genovis is also an important provider of enzymes for the investigation of antibody-drug conjugates used in novel therapeutic approaches. The second business area is providing peptide synthesis services. The company also has a diversified biotechnology infrastructure and offers analysis and synthesis services for peptides in various fields, such as immunotherapy and diagnostics. Genovis' product portfolio includes a variety of enzymes that have broad application in drug research and diagnostic industries. This includes enzymes for antibody proteolysis, enzymes for the synthesis of glycoconjugates, and enzymes for conjugated protein analysis. In addition, the company also offers specialized kits for protein analysis. Genovis kits always include all necessary components such as proteases, buffer systems, and instructions to conduct the offered experiments. In conclusion, Genovis is a leading company in the biotechnology industry that offers innovative enzyme solutions and proteomics tools for a variety of applications in medical research and diagnostics. With its diversified biotechnology infrastructure and dedicated employees, the company can meet the growing needs of its customers in the science and industry sectors and has become a key partner in the healthcare industry. Genovis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genovis stock

EBIT Margin (Operating Margin) of Genovis is 21.32 % in 2026.

EBIT Margin (Operating Margin) of Genovis changed from 35.08 % to 21.32 %, representing a -39.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Genovis since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Genovis with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

Margins — Genovis

All Key Metrics — Genovis